Pan-peroxisome proliferator-activated receptor agonist lanifibranor as a dominant candidate pharmacological therapy for nonalcoholic fatty liver disease
Masato Yoneda, Takashi Kobayashi, Asako Nogami, Michihiro Iwaki, Satoru Saito, Atsushi Nakajima
Abstract
Masato Yoneda, Takashi Kobayashi, Nogami Asako, Michihiro Iwaki, Satoru Saito, Atsushi Nakajima
Topics & Concepts
MedicineNonalcoholic fatty liver diseaseAgonistFatty liverInternal medicinePeroxisome proliferator-activated receptorReceptorGynecologyDiseaseGastroenterologyLiver Disease Diagnosis and TreatmentPeroxisome Proliferator-Activated ReceptorsDiet, Metabolism, and Disease